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Most epidemiological studies evaluating the
prevalence of infectious diseases in correctional
facilities have neglected the prevalence in jails.
While rapid turnover of inmates within jails makes
it difficult to measure and quantify sexually transmitted infection (STI) prevalence, an assessment
conducted by the Centers for Disease Control
and Prevention (CDC) in 1997 found that only 1247% of jails offered routine testing for syphilis,
gonorrhea, or chlamydia, and most offered testing only to symptomatic individuals or those who
requested testing.1 In those jails using symptomatic screening for STIs, less than 8% and 3% of
women and men, respectively, were tested. This
study also documented a common feature of jail
testing schema: approximately 50% of arrestees
were released within 48 hours after intake, yet
most facilities received the inmates' STI test
results more than 48 hours after admission.2
The focus of medical care within jails tends to be
on urgent and/or acute medical conditions, such
as mental illnesses, drug withdrawal, trauma and
tuberculosis, rather than on STIs (see table 1). If
more focus was made on appropriate diagnosis
and treatment of STIs in jails, their transmission
among inmates in prisons should decrease since
jails are often the initial point of entry into a correctional facility. Some have made a strong argument for collaboration between jails, prisons, and
health departments to diagnose, track, and report
STI trends in corrections.3 This has largely been
limited by a lack of resources.
This article will focus on the epidemiology, diagnosis and treatment of the most common STIs
found within jails: syphilis, gonorrhea, chlamydia,
and herpes simplex virus (HSV). The relationship
between HSV and the acquisition and transmission of HIV, and the prevalence and prevention of
hepatitis A and B will also be addressed.

EPIDEMIOLOGY
Syphilis
After an all-time low in 2000, the prevalence of
syphilis in the general US population increased
for the third consecutive year in 2003.4 Between
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2002 and 2003, primary and secondary syphilis
increased by 4.2%, from 2.4 cases5 to 2.5 cases
per 100,000. In 2003, the median percentage of
reactive syphilis tests for adult women and men
entering correctional facilities was 7.5% and
2.3%, respectively (see table 2.) While more than
60% of all primary and secondary syphilis cases
occur among men who have sex with men
(MSM), a more recent analysis6 suggests that
waning immunity within communities may also
contribute to easier acquisition of disease.
There is significant geographical variation in the
prevalence of syphilis, with the highest rates
reported in southern states and in corrections. In
1990, an outbreak of syphilis in New York City
(NYC) led to intake syphilis screening and control
initiatives in NYC jails. In one NYC jail, syphilis
was identified in 3.3% of incoming inmates who
were screened.7
Gonorrhea and Chlamydia
The prevalence of gonorrhea in the general US
population increased until 2003 when rates
decreased 4.8% from 122 cases per 100,000 in
2002 to 116.2 cases per 100,000 in 2003.8 In
2003, the median gonorrhea positivity for both
adult women and men entering corrections was
1.8%.
The prevalence of chlamydia in the general population increased 5.1% from 289.4 cases per
100,000 in 2002 to 304.3 cases per 100,000 in
2003. In 2003, the median chlamydia positivity for
adult women and men entering corrections was
6.3% and 6.4%, respectively. Most male facilities
reporting chlamydia infection were juvenile facilities; rates ranged from 1.3 per 100,000 in a
Colorado juvenile facility to 16 per 100,000 in a
Pennsylvania adult facility. Reported rates of
chlamydia among female facilities range from 1.3
per 100,000 in a Montana facility to 33.5 per
100,000 in an Oklahoma facility, and these estiContinued on page 2
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Table 1: Differences Between Jails and Prisons

(continued from page 1)
mates are likely under-representative. 9
Generally, the rate of diagnosed gonorrhea
is half the rate of diagnosed chlamydia, and
many authorities believe that both of these
STIs are under-reported.
The rate of asymptomatic chlamydia and
gonorrhea among men is unknown. 10
Because most correctional facilities do not
perform intake screening for gonorrhea or
chlamydia, the prevalence of asymptomatic
disease is difficult to estimate.11 Unpublished
data from a recent study on male inmates in
the NYC jail system revealed a relatively
high rate of asymptomatic chlamydial infection, especially in males 35 years and older.
This finding led to the current universal
screening for chlamydia and gonorrhea in all
males older than 35 years in NYC jails.
Additionally, NYC jails test all males for
chlamydia and gonorrhea, regardless of
age, when they present with signs/symptoms of urethritis. Universal STD screening
for females also occurs in NYC jails.
HSV
Genital HSV is notoriously under-diagnosed,
both in the general population and in corrections. Infection is life-long with rare to frequent recurrences of symptomatic and
asymptomatic genital shedding of two
serotypes of virus; most commonly HSV-2,
and sometimes, HSV-1. There is scant data
on HSV prevalence rates, but nationwide, it
is estimated that 50 million individuals (one
of every five Americans) have genital HSV
infection.12
In addition to the discomfort of repeated outbreaks and the risk of transmission, there is
also concern that, like other ulcerative STDs,
HSV may play a role in the transmission and
acquisition of HIV. In a study by Schacker et
al, HIV was isolated from HSV-genital
ulcers13 and an increased risk of HIV acquisition was estimated at 2 to 4 times greater
when HSV was present.14 The results of a
preliminary study in Africa suggested that
suppressive therapy with acyclovir for
patients infected with HSV-2 could be effective in decreasing the risk of HIV acquisition.15
Hepatitis A and B
The prevalence of acute Hepatitis B virus
(HBV) infections has decreased by more
than 60% in the general US population, from
a rate of 8.5 per 100,000 in 1990 to 2.8 per
100,000 in 2002. High rates of disease continue among men 25-39 years and in women
40 years and older. Notably, persons belonging to these age groups represent a large
core population of incarcerated individuals.
While there have been several outbreaks of
HBV in correctional facilities,16 there have

2
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Length of stay
Turnover
Population size
Communication
with local DOH*
Environment
Screening priorities

Age
Staffing

Jails
Unknown, Brief: 24
hours to <one year
Rapid
Usually small
Moderate to extensive

Prisons
Jails and Prisons
Known
Usually > one year
Less rapid
Usually large
Low to moderate

Unstable
Trauma, drug withdrawal, suicide risk,
STIs

Stable
Chronic illness
Tuberculosis
(e.g. hypertension,
diabetes, lung disease)
Older
More stable

Younger
Less stable

Excerpted from Intake and Evaluation in Prisons and Jails, Clinical Practice in Correctional
Medicine, Michael Puisis, D.O. Mosby Incorporated 1998
*Ninth National Survey of HIV/AIDS, Sexually Transmitted Diseases, and Tuberculosis in
Correctional Facilities

Table 2: Syphilis infection rates in selected states 2003, /100,000 pop.
State
Pennsylvania
Texas
Georgia
Alabama
New York
California

General Population
1.3
3.0
6.8
2.5
3.0
3.7

Men Corrections
16.0
5.5 (juveniles)
6.8 (juveniles)
6.4
5.6

Women Corrections
7.7
5.5
7.0
12.4
12.7
6.2

Adapted from the CDC. 2003 Sexually Transmitted Disease Surveillance Report. 2005.

not been any reported outbreaks of hepatitis
A virus (HAV) in corrections.

non-treponemal results may be secondary to
other medical conditions.

Diagnosis of STIs
The diagnosis of STIs within corrections
requires a high index of suspicion, a thorough, non-judgmental sexual history, and a
careful genital examination. All inmates
should be screened for STIs, particularly
when they first enter the system, and
screening should be based on prevalence as
measured by the population served (see
table 4).

In high prevalence settings, in cases where
signs/symptoms of syphilis exist, and where
the history of successful treatment is absent
or unreliable, a Rapid RPR test can be used
to justify empiric treatment while awaiting
confirmatory treponemal test results. Rapid
RPR tests are particularly useful in jail settings where patients may not be available
when confirmatory treponemal test results
return, typically 48 hours later.

Syphilis
The absence of signs and symptoms of
syphilis in infected individuals often makes
diagnosis difficult. When a chancre or generalized rash is present in the clinical setting,
laboratory testing should be used for confirmatory purposes. Syphilis is most often
diagnosed by serologic testing using the
non-treponemal Rapid Plasma Reagin
(RPR) or the Venereal Disease Research
Laboratory (VDRL) test. Treponemal tests
include the Fluorescent Treponemal
Antibody Absorbed [FTA-ABS] and T. pallidum Particle Agglutination [TP-PA]) and are
used to confirm non-treponemal test results.
The result of one serologic test result in an
asymptomatic inmate without laboratory
confirmation (i.e. treponemal test) is insufficient for diagnosis because false-positive

The results of non-treponemal tests correlate with disease activity and usually revert
to negative following successful treatment,
though they may remain positive at low titer
in some individuals. This condition is
referred to as "serofast."
Treponemal antibody tests usually remain
positive for years, and sometimes for the lifetime of the patient, regardless of treatment
or disease activity. Fifteen to 25% of people
may revert to negative two to three years
after successful treatment.
Gonorrhea and Chlamydia
Men with gonorrhea tend to present with
symptoms of pain, dysuria, tenesmus, and
penile and/or anal discharge, dependent
upon the mode of acquisition. Chlamydia
Continued on page 3
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(continued from page 2)
infection may present with scant urethral discharge or symptoms. In contrast to men,
women infected with gonorrhea and chlamydia are often asymptomatic and therefore go
undetected and untreated for longer periods
of time. Left untreated, infection can lead to
pelvic inflammatory disease, tubo-ovarian
pregnancy, and sterility.
The most dramatic change in the diagnosis
of STIs has occurred in the laboratory diagnoses of gonorrhea and chlamydia.
Previously, invasive swabs inserted for samples were required for culture or microscopic
examination. Now, nucleic amplification
testing of fluid samples, including urine, sensitively diagnoses both gonorrhea and
chlamydia. Medical providers should note
that when the nucleic amplification test is
repeated soon after treatment completion,
the repeat test result may be positive.
Consequently, it will be unclear if the person
has been newly infected or has a residual
positive test.
HSV
The clinical diagnosis of genital herpes is
fairly straightforward when the patient presents with pain, vesicles, pustules, or genital
ulcers. These symptoms, in conjunction with
a slight fever and inguinal adenopathy, are
not uncommon in primary genital HSV.
Recurrences tend to be less symptomatic,
but itching, burning, and tingling at the site of
infection or proximal sites may help clarify
the diagnosis. Viral cultures taken with a
swab from the base of an open ulcerative
lesion can identify which type of HSV the
patient is infected with, regardless of the
presence of symptoms. This has prognostic
significance, as genital HSV-2 disease
recurs more frequently than genital HSV-1.
For asymptomatic or vaguely symptomatic
persons, which represents the majority of
HSV infections, diagnosis can be made with
type-specific serology. Western blot is the
gold standard, but other assays are now
available and more cost effective. Serology
is also helpful in determining primary HSV
from recurrent disease. Individuals who are
HSV-2 seropositive and are otherwise
unaware of their infection may be regularly
or intermittently shedding virus from the genital region and therefore infecting sex partners. Giving an inmate this information provides the opportunity to also educate about
risk of HIV acquisition (given the known
increased risk in the presence of HSV-2),
particularly in the MSM population.
Prevention
Promoting safe sex education, abstinence
and safe sexual practices, including the use
of condoms, before, during, and after incarceration is extremely important. Early
screening, diagnosis, and treatment are also

visit IDCR online at www.IDCRonline.org
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Table 3: Hepatitis A and B vaccination in corrections
Hepatitis A
Yes, Age> 40 yearsYes, in
highly endemic communities
(AL, AZ, CA, ID, NV, NM, OK,
OR, SD, UT, WA)
Routine Hepatitis
Yes, when used to identify
serological testing
susceptible candidates for
vaccination
Schedule
0 and 6-12 months (second
dose can be given at any
point following six months if
series in interrupted)
Candidates for vacci- Individuals at-risk, e.g. MSM,
nation
drug abusers, persons with
chronic liver disease or likely
to have significant morbidity if
infected
Post-exposure to
IG 0.02 mg/Kg IMInitiation of
known infectious con- HAV vaccine series is debattact (acute hepatitis A ed
or hepatitis B surface
antigen)
Prevaccination
screening

Hepatitis B
Yes, when prevalence within
facility is >25%-30%
Yes, when used to identify
susceptible candidates for
vaccination
0, 1, and > 6 months
0, 1-2, and 4 months
(if incarcerated < 6 months)
All susceptible incarcerated
individuals

Initiate HBV vaccine series in
known-susceptible person
plus
HBIG 0.06 ml/Kg IM

prudent to prevent transmission within, and
outside of, corrections.

tance from 2.2% to 4.4% was identified in the
United States in 2003.

The prevention of HBV and HAV offers
added avenues of prevention, including education regarding risk of intravenous and
other forms of drug abuse, tattooing risk, and
the utility of pre- and post-exposure vaccination. Pre-exposure vaccination is now recommended during incarceration, regardless
of incarceration length.17 Correctional facilities should develop methods to determine
completion of vaccine series or appropriate
referral upon discharge. There are several
approaches to vaccination, as outlined in
Table 3.

Education to prevent transmission and
acquisition of STIs should be included with
any treatment recommendation. The CDC's
Prevention Advisory Committee has recommended integration of STI and HIV education programs, but the continuing increase in
STIs among MSM may signal a failure of this
integration.19

Treatment
Successful STI treatment depends upon
accurate diagnosis, correct antibiotic or
antiviral prescription, and proper treatment
duration. Multiple guidelines are available,
including the Sexually Transmitted Diseases
Treatment Guidelines published and regularly updated by the CDC.12 (see 'STI 101' in
this issue for treatment chart)
Antimicrobial resistance is an important concern in the treatment of gonorrhea. In April
2004 the CDC changed its' recommendations regarding the use of Fluoroquinolones
for
the
treatment
of
gonorrhea.
Fluoroquinolones are no longer recommended for the treatment of gonorrhea in MSM, or
for the treatment of any case of gonorrhea in
California, Hawaii, and Washington. These
recommendations are based on the following: (1) strains of N. gonorrhea with
decreased susceptibility to Azithromycin
were identified in Missouri in 1999; (2)
strains of N. gonorrhea with decreased susceptibility to Fluroquinolones were identified
in Hawaii and California in 2001;18 (3) an
increase in the rate of Fluroquinolone resis-

Conclusion
This article focused on three of many bacterial STIs and three sexually transmissible
viral infections. These diseases are highly
prevalent within correctional facilities and
have experienced a resurgence in recent
years. While acquisition of healthcare is typically not a priority for inmates, especially
upon entry into jails, medical personnel,
social workers, and correctional officers can,
and should, encourage at-risk individuals to
seek necessary treatment for STIs, and promote education, surveillance, and appropriate STI screening. This is a difficult task in an
era of diminishing resources and limited
time, but is very important in that STIs, even
when asymptomatic, can have devastating
effects on an individual, and on the communities in which we all live.
For helpful up-to-date information on the
management of STDs, visit
http://depts.washington.edu/nnptc/
online_training/std_handbook/index.html
which includes an image gallery, CDC guidelines, and more…
Opportunities for STD clinical training may
be found at
http://depts.washington.edu/nnptc/
core_training/clinical/index.html
Continued on page 4
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Table 4: Methods to improve diagnosis and treatment
Method
Routinely test for common
STIs prevalent within
community at-large. Use
of rapid RPR, urine ligase
for GC and Chlamydia

Targeted screening of
at-risk individuals by
community-determined
high-risk behaviors or
local DOH criteria

Advantage
1. Will likely increase numbers of arrestees diagnosed
with STIs.
2. Urine ligase testing will likely increase acceptance of
testing and accuracy of results.
3. Earlier diagnoses will likely lead to increased
treatment success, decreased transmission within
corrections and likely decrease rates within the
surrounding community.
4. Increased surveillance capability for local
departments of health (DOH).
1. More cost effective than routine screening.
2. Targets high-risk groups.
3. Increases surveillance capability of local DOH.

Use of surrogate markers
for evidence of STIs
(e.g. urine dipstick looking
for nitrate or leukocyte
esterase positive results).

1. Relatively inexpensive with immediate results allowing immediate presumptive treatment.
2. Useful in high prevalence areas with rapid turnovers
of arrestees who may not be available for follow-up
evaluation.
3. Often testing is already in use for diagnosis of other
chronic conditions.

Collaborations with local
DOH

1. Useful to enhance continuity of care into and out of
corrections, for contact tracing, and for partner
notification.
2. Cost savings when previous treatment completion
can be confirmed.
3. Field-delivered therapy can increase completion of
treatment and help contain community spread of disease.
4. Useful for training corrections healthcare workers in
recognition and treatment of STIs.
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Disadvantage
1. Increased laboratory and pharmaceutical
costs on jail budgets.
2. Increased diagnosis may not lead to
equally increased treatment due to rapid jail
turnover.
3. May depend upon awareness of STI
prevalence in outside communities.

1. Dependent upon accurate risk
assessment.
2. Dependent upon reliable patient-derived
information.
3. Likely to require repeat re-assessments
of community-derived risks.
4. Likely to increase diagnoses, but may not
equally increase rates of treatment.
1. Due to poor sample quality, may lead to
over-treatment, as well as treatment of
multiple STIs as co-morbid conditions.
2. Subject to interpretation. Requires quality
standard and training.
3. Offers a range of diagnoses; not a single
diagnosis.
4. Lack of accurate diagnosis hinders DOH
surveillance.
1. Delays in data entry may alter certainty of
treatment completion. This may lead to over
or under-treatment due to unreliable nature
of results.
2. Use of aliases may make documentation
difficult.
3. Local DOH may have different priorities
than correctional facilities.
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Dear Correctional Colleagues:

In the February 17, 2005 issue of the NEJM, Golden et al reports on the "Effect of expedited
treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection". In this
unique study, women and heterosexual men with gonorrhea or chlamydia were randomly
assigned to have their sex partners receive expedited treatment (patients were offered medication to give to their sex partners), or standard referral (patients were advised to refer their
sex partners for treatment and were offered assistance notifying their partners).
The authors successfully showed that expedited treatment was more effective than standard
referral of partners in reducing persistent or recurrent gonorrhea and chlamydial infection.
Also, patients assigned to expedited treatment were significantly more likely to report all of
their sex partners were treated and significantly less likely to report having sex with an
untreated partner. Medication partner packets were distributed to patients or their partners
through pharmacies, the STI clinic in Seattle-King County, or direct mailing. Packets contained either a combination of a single 400-mg dose of cefixime and 1-g sachet of
azithromycin (for gonorrhea) or azithromycin alone (for chlamydia) as well as condoms,
information about the medications and STIs, including a warning about adverse effects, and
instructions to phone staff with questions or concerns.
As many of you know, the success of standard referral of sex partners in the correctional setting is poor, at best, largely due to mistrust of the system, fear of reprimand or infractions and
the like, and fear of breach of confidentiality with subsequent mistreatment by counselors,
medical staff, officers, etc… This study provides a potential strategy to deal with this issue so
that transmission of STIs is reduced and recurrence of disease is minimized, though there
may be some legal barriers to overcome. Innovative solutions, like these, are needed to
effectively reduce the burden of STIs in the correctional setting.
This month, Karl Brown, MD presents an overview of common STIs in jails for our readers
and Steven Scheibel, MD presents a case study of LGV in an inmate infected with HIV. At the
conclusion of this issue, readers should be more familiar with the epidemiology, diagnosis,
and treatment of STIs.
Respectfully,
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Lymphogranuloma venereum (LGV) in an Inmate with HIV

By Steven Scheibel*, MD, Regional Medical Director, Prison Health Services

Disclosures: *Speaker's Bureau: GlaxoSmithKline, Bristol Myers Squibb, Boehringer Ingelheim, and Gilead Sciences
CASE: A 34 year old, HIV-infected Puerto Rican male inmate presents at intake with a complaint of a swollen right inguinal lymph node. He
states that 2 months ago he noticed a swelling in the right groin which gradually increased in size from that of a pea to a tender, mobile mass
the size of an almond. He denies fever, chills, night sweats or other constitutional symptoms. Further, he denies dysuria, penile/rectal ulceration or discharge.
He has 18 months remaining in his sentence. He has sex only with men and has a history of urethral gonorrhea times two and rectal warts. In
2003 he developed a mononucleosis syndrome with generalized lymphadenopathy, fevers and malaise, which was later diagnosed as HIV. On
the outside, he was sexually active, with approximately 50 sex partners, many of whom were anonymous, during the previous 2 months. He only
practices insertive anal intercourse and uses condoms most of the time. He was regularly using crystal methamphetamines and occasionally
used marijuana. He is ARV-naive with a CD4 count of 350 cells/mL and a viral load varying between 30,000-40,000 cells/mL. He has had no
history of opportunistic infections. He reports an allergy to penicillin, which manifested as a rash.
Physical exam is significant for normal vital signs, clear oral cavity, normal cardiovascular and chest exam. Examination of the rectum and
penis/scrotum/testicles are normal without evidence of discharge, lesions or ulcerations. Skin exam shows no rashes or lesions. Lymph node
exam is significant for a 2.5 cm X 1.0 cm tender mobile mass in the right ingiunal area. There is no overlying erythema or drainage. The remainder of the lymph node exam shows multiple 1-2 cm diameter lymph nodes, which are mobile, non-tender and distributed among the axillary,
anterior and posterior cervical and inguinal regions.

Q: What are the differential diagnoses for unilateral tender inguinal
lymph node enlargement in a sexually active HIV-infected male from
Puerto Rico?

Progressive fibrosis leads to strictures in the rectum, draining buboes,
and disfigurement of the external genitalia. The second and late
stages may have associated constitutional signs and/or symptoms.

A: The differential diagnoses include HIV with generalized lymphadenopathy, lymphoma, tuberculosis, chronic fungal infections,
kaposi's sarcoma, cat-scratch disease (bacillary angiomatosis) and a
reaction to a local viral/bacterial infection (e.g. HSV, chancroid,
syphilis, lymphogranuloma venereum [LGV] or Staphylococcus
aureus).

The diagnosis of LGV may be difficult. Perhaps the most definitive test
is culture of an aspirate from the bubo; however, this is only about 50%
sensitive. Other tests available include direct immunofluorescence or
enzyme immunoassay of the bubo aspirate, but may be less sensitive
or not available. A 4-fold rise in antibody titers is suggestive of LGV,
but not specific as there may be cross reactions produced as a result
of infections with other forms of chlamydial infections.1

Q: What tests would you order on the initial evaluation?
A: The Rapid Plasma Reagin (RPR) test was negative and cultures of
the throat and rectum were negative for gonococcus and chlamydia.
DNA amplification test was positive for Chlamydia trachomatis and
negative for Neisseria gonorrhoeae from a urine sample.
Although not conclusive of LGV, the clinical presentation in this patient
is suggestive of an inguinal bubo with the initial site of infection being
the penis or urethra.
Q: What measures, if any, should be taken to evaluate and treat all
sexual contacts over the last 2 months?
A: This sexually transmitted infection (STI) is reportable, and therefore, the public health department should be contacted. Depending on
the particular county/state and available resources, ideally an officer
from the health department would visit the prison and interview the
inmate as well as all potential sexual contacts. All exposed contacts
within the preceeding 2 months would not only need to be cultured for
chlamydia but also screened for HIV and other STIs, such as syphilis.
Because this inmate was diagnosed at intake, all sexual contacts were
likely those in the community from which he came. However, any
potential inmate contacts who may have been exposed to this inmate
(the index case) since he has been in custody should still be explored.
Discussion
LGV is an STI caused by serovars of Chlamydia trachomatis and is
endemic to parts of Africa, India, Southeast Asia, South America and
the Caribbean. The disease process has several stages based upon
the duration of infection. A primary lesion in the genital region characterizes the first stage. The lesion is a shallow ulcer or papule, which
is minimally symptomatic and rapidly heals without scarring. The second stage involves the swelling of locally draining lymph nodes, which
forms into an inflammatory mass with loculations of pus (bubo).

The patient was treated with doxycycline 100 mg twice daily for 21
days with resolution of the bubo and no further recurrence of disease.
The CDC recommendations for treatment of LGV are 21 days of doxycycline. Other agents which are active include co-trimoxazole, erythromycin, minocycline and tetracycline. Also, azithromycin as a 1gram dose has been successful in HIV-infected patients with LGV,
though most of the literature recommends antibiotic treatment for 21
days.1,2 Patients with LGV should be followed weekly for at least 4
weeks or until signs and symptoms have resolved.
A recent report from the Netherlands has shown a dramatic increase
in LGV among men who have sex with men and have unprotected anal
intercourse. These presentations may be markedly atypical in that
most of the men infected with LGV developed gastrointestinal bleeding and inflammation of the rectum and colon.3 These atypical presentations should be distinguished from inflammatory bowel diseases.
Proper diagnosis and treatment of LGV may also decrease the transmission of HIV since it has been shown that other ulcerative diseases,
such as herpes and syphilis, increase risk of HIV acquisition.
For FREE continuing education opportunities related to STIs, visit the
following web site at http://www.stdhivtraining.org/nnptc/about.cfm
References:
1. CDC. 2002 national guideline for the management of lymphogranuloma venereum. MMWR 2002; 51 (RR-6): 1-80.
2. Nieuwenhuis et al. Unusual presentation of early lymphogranuloma venereum in an HIV-1 infected patient: effective treatment with 1gram azithromycin. Sex Transm Infect 2003; 79: 453-55.
3. Title: Lymphogranuloma Venereum among men who have sex with
men - Netherlands, 2002-2003. MMWR 2004; 53 (42): 985-999.
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Treatment Recommendations
DISEASE
Primary and Secondary
syphilis
Early Latent syphilis
(<1 year duration)

RECOMMENDATION
Benzathine penicillin 2.4 million
units IM in a single injection

ALTERNATIVE REGIMEN
1. Doxycycline 100 mg po bid for 14 days OR
2. Tetracycline 500 mg po qid for 14 days

Latent syphilis (>1 year
duration or unknown)

Benzathine penicillin 2.4 million
units IM for three doses at 1-week
intervals

1. Doxycycline 100 mg po bid for 28 days
2. Tetracycline 500 mg qid for 28 days

Neurosyphilis

Aqueous crystalline penicillin G
18-24 million units per day, administered as 3-4 million units IV every
4 hours or continuous infusion,
for 10-14 days

Procaine penicillin 2.4 million units IM once daily
plus Probenicid 500 mg orally four times a day, both
for 10-14 days

Syphilis during pregnancy

Penicillin regimen appropriate for
stage of syphilis

Penicillin allergic pregnant patients should be
desensitized to penicillin

Gonorrhea

1. Ceftriaxone 125 mg IM in a
single dose

1. Ciprofloxacin 500 mg orally in a single dose OR
2. Ofloxacin 400 mg orally in a single dose OR
3. Levofloxacin 250 mg orally in a single dose
Plus, treat for Chlamydia infection if it has not been
ruled out.

Chlamydia

1. Azithromycin 1 g orally in a
single dose OR
2. Doxycycline 100 mg orally twice
daily for 7 days

1. Erythromycin base 500 mg orally four times daily
for 7 days OR
2. Erythromycin ethylsuccinate 800 mg orally four
times daily for seven days OR
3. Ofloxacin 300 mg orally twice daily for 7 days OR
4. Levofloxacin 500 mg orally daily for 7 days

Chlamydia during
pregnancy

1. Erythromycin base 500 mg orally
four times daily for 7 days OR
2. Amoxicillin 500 mg orally three
times daily for 7 days

1. Erythromycin base 500 mg orally four times daily
for 14 days OR
2. Erythromycin ethylsuccinate 800 mg orally four
times daily for 7 days OR
3. Erythromycin ethylsuccinate 400 mg orally four
times daily for 14 days OR
4. Azithromycin 1 g orally in a single dose

HSV, first clinical episode

1. Acyclovir 400 mg three times
daily for 7-10 days OR
2. Valacyclovir 1 g orally twice daily
for 7-10 days OR
3. Famciclovir 250 mg orally three
times daily OR
4. Acyclovir 200 mg orally five
times daily

Genital herpes,
recurrence

Episodic therapy:
1. Above regimens for 5 days
2. Valacyclovir 500 mg for 3-5 days

Suppressive therapy:
1. Acyclovir 400 mg orally twice daily, indefinitely
OR
2. Famciclovir 250 mg orally twice daily OR
3. Valacyclovir 500 mg orally once daily OR
4. Valacyclovir 1 g orally once daily

Hepatitis A*

-

-

Hepatitis B*

-

-

*Chronic hepatitis A and B treatment are beyond the scope of this text.
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SAVE THE
DATES
"Improving the Management
of HIV Disease" - Regional
CME Courses
Los Angeles, CA - April 16, 2005
Chicago, IL - May 2, 2005
Washington, DC - May 20, 2005
San Francisco - June 1, 2005
Visit: www.iasusa.org/
registration/index.html
NCCHC Updates in
Correctional Health Care
April 9-12, 2005
Las Vegas, NV
Visit: www.ncchc.org
AMFAR National HIV/AIDS
Update Conference
April 10-13, 2005
Oakland, CA
Visit: www.amfar.org
ICAAC Meeting
September 21-24, 2005
New Orleans, LA
Visit: www.icaac.org
United States Conference on
AIDS
September 28-October 2, 2005
Houston, TX
Visit: www.nmac.org
Infectious Diseases Society of
America
October 6-9, 2005
San Francisco, CA
Visit: www.idsociety.org
National Conference on
Correctional Health Care
October 8-12, 2005
Denver, CO
Visit: www.ncchc.org
Society of Correctional
Physicians Annual Meeting
October 9, 2005
Denver, CO
Visit: www.corrdocs.org

RESOURCES

8

IN THE NEWS
CONGRATULATIONS!
Dr. Joseph Bick was awarded the Body's HIV
Leadership Award for "Outstanding HIV/AIDS
Clinician."
FDA Approves Pegasys and Copegus as
Only Hepatitis C Treatment for HIV Patients
On February 25, 2005, the Food and Drug
Administration (FDA) approved Pegasys®
(peginterferon alfa-2a) and Copegus® (ribavirin)
for the treatment of chronic hepatitis C virus
(HCV) in HIV/HCV co-infected patients. Pegasys
combination therapy is the first and only FDA
approved regimen for HCV treatment in HIVinfected patients. The FDA based its' approval on
results from the AIDS Pegasys Ribavirin
International Co-infection Trials (APRICOT),
which evaluated chronic HCV treatment in
patients co-infected with HIV/HCV. Pegasys is
dosed at 180 mcg as a subcutaneous injection
administered once weekly. Copegus is available
as a 200 mg tablet, and is administered orally
twice daily as a split dose. Generic ribavirin is
also available at a reduced cost. The FDA is currently reviewing an indication for Pegasys for the
treatment of chronic HBV.
www.ap.org
Switching from Thymidine Analogs Improves
Lypoatrophy
Options for patients with peripheral lipoatrophy
are limited. The MITOX and TARHEEL studies
demonstrated that switching from a thymidine
analog partially reversed lipoatrophy. The ACTG
5125 study demonstrated that switching to a
nucleoside reverse transcriptase inhibitor (NRTI)
sparing regimen increased peripheral lipoatrophy.
Murphy et al analyzed 101 patients who were
receiving the thymidine analogues d4T or AZT as
part of their treatment regimens, with HIV RNA
<500 copies/mL, and clinical evidence of lipoatrophy. Patients were randomized to: (1) switch
thymidine analogues to abacavir (ABC), (2)
switch thymidine analogues to lopinavir/ritonavir
(LPV/r) plus nevirapine (NVP), or (3) delay
switching for 24 weeks. All patients were followed
for 48 weeks post-intervention. Results at 24
weeks showed that subcutaneous thigh fat
increased in the LPV/r + NVP group. There were
SAT increases and VAT:TAT decreases for both
interventions, and a decreased VAT for patients
receiving the ABC regimen. There was also a significant increase in CD4 cell count for patients
receiving the LPV/r + NVP regimen. Murphy et al
concluded that, in patients with lipatrophy, switching d4T or AZT to a non-thymidine analogue or
changing to a NRTI-sparing regimen is associated with significant improvements in SAT, VAT, and
VAT:TAT, while maintaining virologic control and
improving CD4 cell count.

Murphy Robert, et al. Switching to a thymidine
analog-sparing or nucleoside-sparing regimen
improves lipoatrophy: 24-week results of a
prospective randomized clinical trial, AACTG
5110. 12th Conference on Retroviruses and
Opportunistic Infections. Session 10 oral
abstracts. Boston, MA: February 23, 2005.
Tipranivir/Ritonavir is Superior to
Lopinavir/Ritonavir
Cooper et al analyzed the RESIST trials to compare the efficacy of Tipranivir/ritonavir (TPV/r)
and Lopinavir/ritonavir (LPV/r), and to assess the
role of additional active drugs in the optimized
background regimen (OBR). Of the 1,483
patients randomized and treated in the two trials,
1,159 were available for analysis at 24 weeks. At
24 weeks, in the TPV/r and LPV/r groups, 34%
and 18%, respectively, had viral loads <400
copies/mL; 24% and 11%, respectively, had viral
loads <50 copies/mL, and CD4 cell count
increase was +31 cells and +6 cells, respectively.
The 24-week treatment response increased in
both the TPV/r and LPV/r groups with the use of
additional active background antiretroviral
agents. Cooper et al concluded that TPV/r is
superior to LPV/r in PI-experienced HIV-infected
patients.
Cooper David, et al. 24-Week RESIST study
analyses: the efficacy of tipraniavir/ritonavir is
superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized
background regimen. 12th Conference on
Retroviruses and Opportunistic Infections.
Session 97 poster abstracts. Boston, MA:
February 24, 2005.
Tenofovir for HIV/HBV Co-infection
Peters et al assessed the non-inferiority of TDF
with adefovir dipivoxil (ADV) with respect to HBV
DNA, assessed the clinical response to ADV versus TDF, and evaluated the safety and tolerability of ADV and TDF. Subjects received daily either
ADV 10mg plus TDF placebo or TDF 300mg plus
ADV placebo for up to 96 weeks. Non-inferiority
was defined with a tolerance of -1 log. Mean
log10 average change from baseline to 44 weeks
was -4.44 and -3.21 in the TDF and ADV arms,
respectively. Peters et al concluded that both
ADV and TDF successfully lower HBV DNA and
are safe and efficacious in HIB/HBV co-infected
patients over 48 weeks.
Peters Marion, et al. Tenofovir disoproxil
fumarate is not inferior to adefovir dipivoxil for the
treatment of hepatitis B virus in subjects who are
co-infected with HIV: results of ACTG A5127.
12th Conference on Retroviruses and
Opportunistic Infections.
Session 31 oral
abstracts. Boston, MA: February 24, 2005.

CDC. National Center for HIV, STD and TB Prevention. Division of Sexually Transmitted Diseases
http://www.cdc.gov/nchstp/dstd/aboutdiv.htm
National Network of STD/HIV Prevention Training Centers
http://depts.washington.edu/nnptc/
Seattle STD/HIV Prevention Training Center
http://depts.washington.edu/seaptc/
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CONTINUING MEDICAL EDUCATION CREDIT

Brown Medical School designates this educational activity for one hour in category one credit toward the AMA Physician’s Recognition
Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions.
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through September 30, 2005.
The estimated time for completion of this activity is one hour and there is no fee for participation.

1. The following statements regarding syphilis are true:
a. Approximately 60% of all syphilis cases occur among men
who have sex with men.
b. The highest prevalence rates of syphilis are reported
among southern states and in corrections.
c. Non-treponemal tests are used to confirm treponemal
tests.
d. A and B
e. All of the above
2. Approximately what percentage of male inmates entering correctional facilities present with syphilis, gonorrhea, and
Chlamydia, respectively?
a. 7.5%, 2.3%, and 6.4%
b. 2.3%, 1.8%, and 6.4%.
c. 6.4%, 1.8%, and 2.3%
d. 3.4%, 1.8%, and 6.3%
e. None of the above
3. It is estimated that approximately 60 million individuals worldwide have genital HSV infection. True or False?
a. True
b. False
4. The following statements regarding the diagnosis of STIs are
all true, except:
a. Syphilis is most often diagnosed by serologic testing,
which may include the RPR or VDRL tests.
b. Nucleic amplification testing of urine samples can be used
to diagnose syphilis, gonorrhea, and Chlamydia.
c. The acute phase of HSV infection often presents as
genital ulcers, inguinal adenopathy, and slight fever.
d. Gonorrhea and Chlamydia infection in females is often
asymptomatic.
e. None of the above
5. The CDC recommendations for treatment of LGV are closest
to which of the following?
a. 100 mg doxycycline for 12 days.
b. 50 mg doxycycline for 21 days.
c. 100 mg doxycycline fpr 21 days.
d. 50 mg doxycycline for 12 days.
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